Amylyx Pharmaceuticals, Inc.
AMLX
$14.64
$0.432.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 52.70% | 42.99% | 69.77% | -893.62% | -447.98% |
| Total Depreciation and Amortization | -45.70% | -32.21% | -50.48% | -46.84% | -26.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -85.95% | -58.30% | -95.65% | -27.02% | 439.51% |
| Change in Net Operating Assets | 81.74% | 214.58% | -5,711.59% | -1,815.03% | 68.89% |
| Cash from Operations | 26.95% | 62.08% | -8,043.97% | -535.45% | -704.22% |
| Capital Expenditure | -226.32% | 80.90% | 83.58% | -10,075.00% | 105.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -86.44% | 179.70% | -5,026.41% | 375.56% | 136.01% |
| Cash from Investing | -86.51% | 179.40% | -5,430.77% | 210.54% | 135.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 441.55% | 53.19% | -32.92% | -57.35% | -50.10% |
| Repurchase of Common Stock | -426.52% | -415.00% | 32.70% | 67.52% | -332.63% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 239,407.50% | -214.81% | 50,023.66% | -52.17% | -91.00% |
| Foreign Exchange rate Adjustments | -36.02% | 1,658.97% | 279.09% | -321.52% | 276.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6,934.50% | 98.24% | -5,121.08% | -84.10% | 97.83% |